

Serial No. 10/569,819, filed February 27, 2006
Docket No. 1103326-0904
Page 2 of 7

RECEIVED
CENTRAL FAX CENTER

JUL 16 2007

Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

1. (Previously presented) An adamantan ammonium salt of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfanyl]-1*H*-benzimidazole (omeprazole) or (*S*)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfanyl]-1*H*-benzimidazole (esomeprazole).
2. (Previously presented) The adamantan ammonium salt according to claim 1, wherein the salt is a 1-adamantan ammonium salt of omeprazole.
3. (Previously presented) The adamantan ammonium salt according to claim 1, wherein the salt is a 1-adamantan ammonium salt of esomeprazole.
4. (Previously presented) The adamantan ammonium salt according to claim 1, wherein the salt is a 2-adamantan ammonium salt of omeprazole.
5. (Previously presented) The adamantan ammonium salt according to claim 1, wherein the salt is a 2-adamantan ammonium salt of esomeprazole.
6. (Previously presented) The adamantan ammonium salt according to claim 1, wherein the salt is crystalline.
7. (Previously presented) A process for the preparation of the adamantan ammonium salt according to claim 1, whercin the process comprises the steps of:
 - a) dissolving omeprazole or esomeprazole in an organic solvent;
 - b) adding an adamantan amine and precipitating the desired salt; and
 - c) isolating and drying the obtained salt.
8. (Previously presented) The process according to claim 7, wherein the organic solvent is selected from the group consisting of acetonitrile, ethyl acetate, *tert*-butyl methyl ether, methanol, and mixtures thereof.

Serial No. 10/569,819, filed February 27, 2006
Docket No. 1103326-0904
Page 3 of 7

9. (Previously presented) The process according to claim 7, wherein the organic solvent is selected from the group consisting of acetonitrile, ethyl acetate, methanol, and mixtures thereof.

10. (Previously presented) The process according to claim 7, wherein the obtained salt is an adamantan ammonium salt of omeprazole.

11. (Previously presented) The process according to claim 7, wherein the obtained salt is an adamantan ammonium salt of esomeprazole.

12. (Previously presented) A pharmaceutical composition comprising the adamantan ammonium salt of omeprazole or esomeprazole according to any one of claims 1 to 6 as active ingredient and one or more pharmaceutically acceptable excipients.

13. (Canceled)

14. (Currently amended) A method for inhibiting treatment of a gastric acid secretion related condition, which method comprises administering a therapeutically effective amount of the adamantan ammonium salt of omeprazole or esomeprazole according to any one of claims 1 to 6 to a patient in need thereof.

15. (Withdrawn) The pharmaceutical composition according to claim 12, further comprising one or more additional therapeutic ingredients.